Finance

Lists
ICY:FRA
Incyte Corp
100,00 €
-0,05%
(-0,050) 1D
12-окт., 22:00:00 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for ICY...
Open
100,00 €
High
100,00 €
Low
100,00 €
Mkt. cap
22,57 млд
Avg. vol.
34,00
Volume
0,00
52-wk high
115,40 €
52-wk low
72,28 €
No. of employees
3 миң
Open
100,00 €
High
100,00 €
Low
100,00 €
Mkt. cap
22,57 млд
Avg. vol.
34,00
Volume
0,00
52-wk high
115,40 €
52-wk low
72,28 €
No. of employees
3 миң
News stories
From web sources and news partners
Profile
Incyte Corporation is an American multinational pharmaceutical company with headquarters in Wilmington, Delaware. The company currently operates manufacturing and R&D locations in North America, Europe, and Asia. Incyte Corporation currently develops and manufactures prescription biopharmaceutical medications in multiple therapeutic areas including oncology, inflammation, and autoimmunity. Wikipedia
About Incyte Corp
CEO-
Employees2,84 миң
Founded2002
HeadquartersУилмингтон, Делавэр, Америка Кошмо Штаттары
Sector-
Websiteincyte.com
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. мар.
2026-ж. июн.
Revenue
1,37 млд
1,51 млд
1,27 млд
1,67 млд
Cost of goods sold
605,58 млн
732,55 млн
620,43 млн
621,91 млн
Cost of revenue
605,58 млн
732,55 млн
620,43 млн
621,91 млн
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
328,29 млн
388,96 млн
327,06 млн
350,72 млн
Operating expense
328,29 млн
388,96 млн
327,06 млн
350,72 млн
Total operating expenses
933,87 млн
1,12 млд
947,49 млн
972,63 млн
Operating income
432,11 млн
385,32 млн
325,19 млн
701,41 млн
Other non operating income
3,25 млн
4,22 млн
1,75 млн
5,26 млн
EBT including unusual items
482,31 млн
389,94 млн
343,60 млн
751,51 млн
EBT excluding unusual items
461,55 млн
419,71 млн
360,06 млн
744,21 млн
Income tax expense
58,14 млн
90,66 млн
40,27 млн
165,91 млн
Effective tax rate
12,05%
23,25%
11,72%
22,08%
Other operating expenses
-
-
-
-
Net income
424,17 млн
299,28 млн
303,33 млн
585,60 млн
Net profit margin
31,05%
19,86%
23,83%
34,98%
Earnings per share
2,26
1,80
1,81
3,09
Interest and investment income
26,78 млн
30,75 млн
33,69 млн
38,12 млн
Interest expense
-592,00 миң
-582,00 миң
-569,00 миң
-582,00 миң
Net interest expenses
26,19 млн
30,17 млн
33,12 млн
37,54 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
456,13 млн
409,30 млн
348,99 млн
727,89 млн
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google колдонмолору